Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.

The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.

News Market Reaction – CBLL

+0.97%

+0.97% Session move

In the trading session that priced this news, CBLL gained 0.97%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43^rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time. 

Event: 43^rd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2025
Time: 7:30 a.m. PST 

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About Ceribell, Inc.
Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.  

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com 

Media Contact
Corrie Rose
Press@ceribell.com

FAQ

When is Ceribell (CBLL) presenting at the 2025 J.P. Morgan Healthcare Conference?

Ceribell (CBLL) is scheduled to present at the conference on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time.

How can investors watch Ceribell's (CBLL) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live and archived webcast available in the Investor Relations section of Ceribell's website at investors.ceribell.com.

What is Ceribell's (CBLL) main business focus?

Ceribell (CBLL) is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.

Who will be presenting for Ceribell (CBLL) at the 2025 J.P. Morgan Healthcare Conference?

Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will be presenting at the conference.